
Oncology NEWS International
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
SOUTH SAN FRANCISCOGenentech Inc. has submitted a supplemental Biologics License Application (sBLA) to FDA for bevacizumab (Avastin) in combination with platinum-based chemotherapy for first-line treatment of advanced, non-squamous, non-small-cell lung cancer (NSCLC). The company has requested priority review on the submission. In a phase III trial (E4599) in patients with locally advanced, metastatic, or recurrent NSCLC, Avastin plus paclitaxel and carboplatin improved overall survival by 25%, compared with chemotherapy alone.
Articles in this issue
almost 20 years ago
NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Schedulealmost 20 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaalmost 20 years ago
New Imaging, ChemoRT Recommendations From NCCNalmost 20 years ago
Panitumumab Improves PFS in Advanced Colon Caalmost 20 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsalmost 20 years ago
Growing Evidence Supports Stem Cell Hypothesis of Canceralmost 20 years ago
FDA Approves New Every-3-Week Dosing for Aranespalmost 20 years ago
Telephone Often Delivers News of Breast Cancer Diagnosisalmost 20 years ago
IND Submitted for CYT-500Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































